Worth Sharing

WS

Stories That Matter

50% Success in HIV Vaccine Tests Leads to Human Trials

50% Success in HIV Vaccine Tests Leads to Human Trials
Human trials are now underway in the U.S., Africa and Asia for a new vaccine that completely prevented HIV in half the test subjects.

A new, experimental HIV vaccine is being tested in humans after it completely prevented the disease in half the monkeys it was given to.

Drug company Johnson & Johnson is now testing the vaccine on 400 healthy human volunteers in the U.S., South Africa, Eastern Africa and Thailand.

The company believes the vaccine will work even better on humans than on animals.

The vaccine works in two steps, similar to an Ebola vaccine the company is also developing.

The first dose given to the monkeys included a weakened cold virus and genetic bits of an animal version of HIV — simian immunodeficiency virus (SIV). Once doctors saw an immune system response, they gave the primates a second shot that contained an SIV protein that triggered the immune system to fight off the virus.

Drug company Johnson & Johnson is now testing the vaccine on 400 healthy human volunteers in the U.S., South Africa, Eastern Africa and Thailand.

The company believes the vaccine will work even better on humans than on animals.

The vaccine works in two steps, similar to an Ebola vaccine the company is also developing.

The first dose given to the monkeys included a weakened cold virus and genetic bits of an animal version of HIV — simian immunodeficiency virus (SIV). Once doctors saw an immune system response, they gave the primates a second shot that contained an SIV protein that triggered the immune system to fight off the virus.

Researchers published their findings in the journal Science.

If the first human trials go well, a wider study will start within the next two years to determine what the exact doses for people should be.

(READ more at the Daily Mail) – Photo by snre, CC license

Pass Along This Medical Breakthrough… (Share below)

About author

Be the first to comment

Leave a Comment